Allergy Immunotherapies Market, By Type (Subcutaneous Immunotherapy, and Sublingual Immunotherapy), By Application (Allergic Rhinitis, Allergic Asthma, and Other), Industry Trends, Estimation & Forecast, 2014-2025

Check Today's Best Price

$3500 Buy Now
The global allergy immunotherapies market is valued at XX million US$ in 2018 is expected to reach 3635.2 million US$ by the end of 2025, growing at a CAGR of 10.8% during 2019-2025.
  • Market Overview

    The global allergy immunotherapies market is valued at XX million US$ in 2018 is expected to reach 3635.2 million US$ by the end of 2025, growing at a CAGR of 10.8% during 2019-2025.

    Allergen immunotherapy, also known as desensitization or hypo-sensitization, is a medical treatment for some types of allergies. It is useful for environmental allergies, allergies to insect bites, and asthma. Its benefit for food allergies is unclear and thus not recommended. Immunotherapy involves exposing people to larger and larger amounts of allergen in an attempt to change the immune system’s response.

    The primary therapeutic goals of allergy immunotherapy (AIT) include reducing symptoms, reducing symptomatic medication use, and improving allergy related quality of life. The evidence is strong that AIT achieves these goals and can alter the course of the disease, with benefits persisting in many patients for several years after treatment discontinuation.

    Allergy Immunotherapies Market volume -2014-2025

    Market Driver

    Increasing prevalence of Allergy worldwide is boosting the global allergy immunotherapies market. For instance, globally, allergic rhinitis affects between 10% and 30 % of the population. Around 7.8% of people aged 18 and over in the U.S. have Allergic Rhinitis (hay fever). The prevalence of allergic rhinitis in the United States ranges from 3% to 19%, and 30 to 60 million people are affected each year. The development of allergic rhinitis before 20 years of age occurs in 80% of cases. Asthma and allergic diseases, such as allergic rhinitis (hay fever), food allergy, and eczema, are common for all age groups in the United States. Allergies are the 6th leading cause of chronic illness in the U.S. More than 50 million Americans suffer from allergies each year. Immunotherapy (allergy shots) helps reduce hay fever symptoms in about 85% of people with allergic rhinitis. National Health Interview Survey (NHIS), 8.4% of US children under age 18 suffered from hay fever, 10% from respiratory allergies, 5.4% from food allergies, and 11.6% from skin allergies in 2015.

    Market Restraint

    Immunotherapy does not work on all type of allergy. Allergy immunotherapy are ineffective for treating food allergies and urticaria. Urticaria causes chronic hives related to an underlying disease such as hyperthyroidism or lupus. In addition, insect venom allergies such as bee stings or spider bites cannot be prevented by allergy immunotherapy.

    Segment Analysis

    Based on product type, the global allergy immunotherapies market is broadly segmented as Subcutaneous Immunotherapy, and Sublingual Immunotherapy. In 2018 Subcutaneous Immunotherapy is the dominant segment, and it accounts for approximately 60% of the market.

    Subcutaneous Immunotherapy (SCIT) is a therapy for allergic disease. It provides symptomatic relief while modifying the allergic disease by targeting the underlying immunological mechanism. Subcutaneous Immunotherapy is for the treatment of asthma, allergic rhinitis/rhinoconjunctivitis, and stinging insect hypersensitivity.

    The regulatory approval for Subcutaneous Immunotherapy is one of the prominent factor boosting the Allergy Immunotherapies market. For instance, August 12, 2018, Genentech, a member of the Roche Group, have received the U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation for Xolair (omalizumab) for the prevention of severe allergic reactions following accidental exposure to one or more foods in people with allergies. Breakthrough Therapy Designation is designed to expedite the development and review of medicines intended to treat serious or life-threatening diseases. Xolair for subcutaneous used as an injectable prescription medicine to treat moderate to severe persistent asthma in patients six years of age or older whose asthma symptoms are not controlled by asthma medicines called inhaled corticosteroids.

    Sublingual Immunotherapy has shown significant growth in 2018, and it is expected to grow in the forecasting years, due to the regulatory approval for sublingual immunotherapy. For instance, March 1, 2017, Catalent Pharma Solutions Limited, has received the U.S. Food and Drug Administration approval for Odactra, the allergen extract to be administered under the tongue (sublingually) to treat house dust mite (HDM)-induced nasal inflammation (allergic rhinitis), with or without eye inflammation (conjunctivitis), in people 18 through 65 years of age.

    Allergy Immunotherapies Market- By Type

    Regional Analysis

    The global allergy immunotherapies market is segmented into North America, Europe, Asia-Pacific, South America, Middle East & Africa.

    North America is dominating the global allergy immunotherapies market, due to the increasing incidence of food allergies in the U.S. For instance, an estimated 200,000 emergency room visits each year due to food allergy. Around 8 percent of children and 4 percent of adults in the U.S. are affected by food allergies, and the incidence is increasing.

    The North America allergy immunotherapies (Allergy Immunotherapy) market size was XX million USD in 2017, and it will be 1060.5 million USD in 2025, with a CAGR 10.8% from 2018 to 2025.

    Europe is the second largest market for allergy immunotherapies in 2018, due to the increasing clinical trials by the companies. For instance, November 20, 2018, Stallergenes Greer, is a U.K based biopharmaceutical company specializing in treatments for respiratory allergies, has completed phase III clinical trial to evaluate the efficacy and safety of its sublingual allergy immunotherapy tablet STAGR320 for the treatment of house dust mite (HDM)-induced allergic rhinitis.

    Competitive Analysis

    The major players include ALK-Abello, Allergy Therapeutics, Circassia, DBV Technologies, HAL, Holister Stier, Leti, Merck KGaA (Allergopharma), Stallergenes Greer, and Anergis S.A.

    The regulatory approval for allergy immunotherapies is boosting the global allergy immunotherapies market. For instance, October 10, 2017, Stallergenes Greer plc, a biopharmaceutical company specializing in treatments for respiratory allergies, have received the approval for ACTAIR, its immunotherapy tablet for the treatment of house dust mite (HDM) induced respiratory allergy, from the Australian health authorities (TGA, Therapeutic Goods Administration).

    Global Allergen immunotherapy Market

    • Consumption by Regions
      • North America
      • Europe
      • China
      • Japan
      • Rest of World
    • Segment by Type
      • Subcutaneous Immunotherapy
      • Sublingual Immunotherapy
    • Segment by Application
      • Allergic Rhinitis
      • Allergic Asthma
      • Other
    • The following manufacturers are covered:
      • ALK-Abello
      • Allergy Therapeutics
      • Circassia
      • DBV Technologies.
      • HAL
      • Holister Stier
      • Leti
      • Merck KGaA (Allergopharma)
      • Stallergenes Greer
      • Anergis S.A.
    keyboard_arrow_up
  • Table of Contents

    1 Allergy Immunotherapies (Allergy Immunotherapy) Market Overview
    1.1 Allergy Immunotherapies (Allergy Immunotherapy) Product Overview
    1.2 Allergy Immunotherapies (Allergy Immunotherapy) Segment by Types
    1.2.1 Global Allergy Immunotherapies (Allergy Immunotherapy) Sales Comparison by Types (2013-2025)
    1.2.2 Global Allergy Immunotherapies (Allergy Immunotherapy) Sales Market Share by Types in 2017
    1.2.3 Subcutaneous Immunotherapy
    1.2.4 Sublingual Immunotherapy
    1.3 Global Allergy Immunotherapies (Allergy Immunotherapy) Segment by Applications
    1.3.1 Global Allergy Immunotherapies (Allergy Immunotherapy) Sales Comparison by Applications (2013-2025)
    1.3.2 Allergic Rhinitis
    1.3.3 Allergic Asthma
    1.3.4 Other
    1.4 Global Allergy Immunotherapies (Allergy Immunotherapy) Market by Regions
    1.4.1 Global Allergy Immunotherapies (Allergy Immunotherapy) Market Size by Regions
    1.4.2 North America Allergy Immunotherapies (Allergy Immunotherapy) Status and Prospect (2013-2025)
    1.4.3 Asia-Pacific Allergy Immunotherapies (Allergy Immunotherapy) Status and Prospect (2013-2025)
    1.4.4 Europe Allergy Immunotherapies (Allergy Immunotherapy) Status and Prospect (2013-2025)
    1.4.5 South America Allergy Immunotherapies (Allergy Immunotherapy) Status and Prospect (2013-2025)
    1.4.6 Middle East and Africa Allergy Immunotherapies (Allergy Immunotherapy) Status and Prospect (2013-2025)
    1.5 Global Allergy Immunotherapies (Allergy Immunotherapy) Market Size
    1.5.1 Global Allergy Immunotherapies (Allergy Immunotherapy) Revenue Status and Outlook (2013-2025)
    1.5.2 Global Allergy Immunotherapies (Allergy Immunotherapy) Sales Status and Outlook (2013-2025)

    2 Global Allergy Immunotherapies (Allergy Immunotherapy) Market Competition by Manufacturers
    2.1 Global Allergy Immunotherapies (Allergy Immunotherapy) Sales by Manufacturers (2013-2018)
    2.2 Global Allergy Immunotherapies (Allergy Immunotherapy) Revenue and Share by Manufacturers (2013-2018)
    2.3 Manufacturers Allergy Immunotherapies (Allergy Immunotherapy) Manufacturing Base Distribution, Sales Area, Product Types
    2.4 Allergy Immunotherapies (Allergy Immunotherapy) Market Competitive Situation and Trends
    2.4.1 Allergy Immunotherapies (Allergy Immunotherapy) Market Concentration Rate
    2.4.2 Allergy Immunotherapies (Allergy Immunotherapy) Market Share of Top 3 and Top 5 Manufacturers

    3 Global Allergy Immunotherapies (Allergy Immunotherapy) Sales, Revenue by Regions
    3.1 Global Allergy Immunotherapies (Allergy Immunotherapy) Sales and Market Share by Regions (2013-2018)
    3.2 Global Allergy Immunotherapies (Allergy Immunotherapy) Revenue by Regions (2013-2018)
    3.3 Global Allergy Immunotherapies (Allergy Immunotherapy) Sales, Revenue, and Gross Margin (2013-2018)
    3.4 North America Allergy Immunotherapies (Allergy Immunotherapy) Sales, Revenue, and Gross Margin (2013-2018)
    3.5 Europe Allergy Immunotherapies (Allergy Immunotherapy) Sales, Revenue, and Gross Margin (2013-2018)
    3.6 Asia-Pacific Allergy Immunotherapies (Allergy Immunotherapy) Sales, Revenue, and Gross Margin (2013-2018)
    3.7 South America Allergy Immunotherapies (Allergy Immunotherapy) Sales, Revenue, and Gross Margin (2013-2018)
    3.8 Middle East and Africa Allergy Immunotherapies (Allergy Immunotherapy) Sales, Revenue, and Gross Margin (2013-2018)

    4 Global Allergy Immunotherapies (Allergy Immunotherapy) Sales, Revenue, Price Trend by Types
    4.1 Global Allergy Immunotherapies (Allergy Immunotherapy) Sales by Types (2013-2018)
    4.2 Global Allergy Immunotherapies (Allergy Immunotherapy) Revenue by Types (2013-2018)

    5 Global Allergy Immunotherapies (Allergy Immunotherapy) Market Analysis by Applications
    5.1 Global Allergy Immunotherapies (Allergy Immunotherapy) Sales and Market Share by Applications (2013-2018)
    5.2 Global Allergy Immunotherapies (Allergy Immunotherapy) Sales Growth Rate by Applications (2013-2018)

    6 Global Allergy Immunotherapies (Allergy Immunotherapy) Manufacturers Profiles/Analysis
    6.1 ALK-Abelló A/S
    6.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Its Competitors
    6.1.2 Allergy Immunotherapies Product Category, Application, and Specification
    6.1.2.1 ACARIZAX®
    6.1.3 ALK-Abelló A/S Allergy Immunotherapies Production, Revenue, and Gross Margin (2013-2018)
    6.1.4 Main Business/Business Overview
    6.2 Allergy Therapeutics
    6.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Its Competitors
    6.2.2 Allergy Immunotherapies Product Category, Application, and Specification
    6.2.2.1 Pollinex Trees
    6.2.3 Allergy Therapeutics Allergy Immunotherapies Production, Revenue, and Gross Margin (2013-2018)
    6.2.4 Main Business/Business Overview
    6.3 Circassia Pharmaceuticals plc
    6.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Its Competitors
    6.3.2 Allergy Immunotherapies Product Category, Application, and Specification
    6.3.2.1 NIOX VERO
    6.3.3 Circassia. Allergy Immunotherapies Production, Revenue, and Gross Margin (2013-2018)
    6.3.4 Main Business/Business Overview
    6.4 DBV Technologies
    6.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Its Competitors
    6.4.2 Allergy Immunotherapies Product Category, Application, and Specification
    6.5.2.1 Viaskin Peanut
    6.4.3 DBV Technologies Allergy Immunotherapies Production, Revenue, and Gross Margin (2013-2018)
    6.4.4 Main Business/Business Overview
    6.5 HAL Allergy Group
    6.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Its Competitors
    6.5.2 Allergy Immunotherapies Product Category, Application, and Specification
    6.5.2.1 Subcutaneous Immunotherapy
    6.5.3 HAL Allergy Group Allergy Immunotherapies Production, Revenue, and Gross Margin (2013-2018)
    6.5.4 Main Business/Business Overview
    6.6 Jubilant HollisterStier LLC
    6.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Its Competitors
    6.6.2 Allergy Immunotherapies Product Category, Application, and Specification
    6.6.2.1 Tree Pollen
    6.6.2.2 Grass Pollen
    6.6.3 Jubilant HollisterStier LLC Allergy Immunotherapies Production, Revenue, and Gross Margin (2013-2018)
    6.6.4 Main Business/Business Overview
    6.7 Laboratorios LETI, S.L.U.
    6.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Its Competitors
    6.6.2 Allergy Immunotherapies Product Category, Application, and Specification
    6.6.2.1 Subcutaneous administration
    6.6.2.2 Sublingual administration
    6.6.3 Laboratorios LETI, S.L.U. Allergy Immunotherapies Production, Revenue, and Gross Margin (2013-2018)
    6.6.4 Main Business/Business Overview
    6.8 Merck KGaA
    6.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Its Competitors
    6.8.2 Allergy Immunotherapies Product Category, Application, and Specification
    6.8.2.1 Allergen-specific immunotherapy
    6.8.3 Merck KGaA Allergy Immunotherapies Production, Revenue, and Gross Margin (2013-2018)
    6.8.4 Main Business/Business Overview
    6.9 Stallergenes Greer plc
    6.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Its Competitors
    6.9.2 Allergy Immunotherapies Product Category, Application, and Specification
    6.9.2.1 Sublingual products
    6.9.2.2 Subcutaneous products
    6.9.3 Stallergenes Greer plc Allergy Immunotherapies Production, Revenue, and Gross Margin (2013-2018)
    6.9.4 Main Business/Business Overview
    6.10 Anergis S.A.
    6.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Its Competitors
    6.10.2 Allergy Immunotherapies Product Category, Application, and Specification
    6.10.2.1 AllerT
    6.10.2.2 COP Allergy Vaccine for Ragweed Pollen
    6.10.2.3 COP Allergy Vaccine for House Dust Mites
    6.10.3 Anergis S.A. Allergy Immunotherapies Production, Revenue, and Gross Margin (2013-2018)
    6.10.4 Main Business/Business Overview

    7 Factors Influencing
    7.1 GDP for Major Regions
    7.2 Population and Labor Considered for Forecast
    7.3 Disposable Income Considered for Forecast

    8 Global Allergy Immunotherapies (Allergy Immunotherapy) Market Forecast
    8.1 Global Allergy Immunotherapies (Allergy Immunotherapy) Sales, Revenue Forecast
    8.1.1 Global Allergy Immunotherapies (Allergy Immunotherapy) Sales and Growth Rate Forecast (2018-2025)
    8.1.2 Global Allergy Immunotherapies (Allergy Immunotherapy) Revenue and Growth Rate Forecast (2018-2025)
    8.2 Global Allergy Immunotherapies (Allergy Immunotherapy) Sales and Revenue Forecast by Regions (2018-2025)
    8.2.1 North America Allergy Immunotherapies (Allergy Immunotherapy) Sales and Revenue Forecast (2018-2025)
    8.2.2 Europe Allergy Immunotherapies (Allergy Immunotherapy) Sales and Revenue Forecast (2018-2025)
    8.2.3 Asia-Pacific Allergy Immunotherapies (Allergy Immunotherapy) Sales and Revenue Forecast (2018-2025)
    8.2.4 South America Allergy Immunotherapies (Allergy Immunotherapy) Sales and Revenue Forecast (2018-2025)
    8.2.5 Middle East and Africa Allergy Immunotherapies (Allergy Immunotherapy) Sales and Revenue Forecast (2018-2025)
    8.3 Global Allergy Immunotherapies (Allergy Immunotherapy) Sales and Revenue Forecast by Type (2018-2025)
    8.4 Global Allergy Immunotherapies (Allergy Immunotherapy) Sales Forecast by Application (2018-2025)

    9 Research Findings and Conclusion

    10 Methodology and Data Source
    10.1 Methodology/Research Approach
    10.1.1 Research Programs/Design
    10.1.2 Market Size Estimation
    10.1.3 Market Breakdown and Data Triangulation
    10.2 Data Source
    10.2.1 Secondary Sources
    10.2.2 Primary Sources
    10.3 Disclaimer

    keyboard_arrow_up
    • List of Companies
      • ALK-Abello
      • Allergy Therapeutics
      • Circassia
      • DBV Technologies.
      • HAL
      • Holister Stier
      • Leti
      • Merck KGaA (Allergopharma)
      • Stallergenes Greer
      • Anergis S.A.
    keyboard_arrow_up


    • Keep your personal detail safe with us. Privacy Policy
      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CLIENTS

SHARE YOUR CART